The use of gold compounds decreased since the 1990s because of numerous side effects and monitoring requirements, limited efficacy, and very slow onset of action.

Nevertheless, a slow onset, long-duration agonist seems like a reasonable approach.

Disadvantages are the slow onset of adequate anaesthesia, inadequate analgesia for larger procedures, and toxicity of absorbed medication.

Megaloblastic anemia has a rather slow onset, especially when compared to that of other anemias.

With its sweetness having a slow onset and decline similar to monellin and thaumatin.